XOMA Appoints Tom Klein to Newly Created Position of Chief Commercial Officer

XOMA Appoints Tom Klein to Newly Created Position of Chief Commercial Officer

BERKELEY, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation
(Nasdaq:XOMA), a leader in the discovery and development of therapeutic
antibodies, today announced Tom Klein has joined the Company as Chief
Commercial Officer, a newly created position reporting to John Varian, XOMA's
Chief Executive Officer. Mr. Klein brings over 25 years of successful brand
commercialization leadership, with an expertise in commercializing biologic
products to medical specialists. Mr. Klein joins XOMA from Genentech, where he
was Vice President, Business Unit Head Virology and Specialty Care.

"We created an executive-level position for commercial operations for two
reasons.First, with the gevokizumab Phase 3 NIU program expected to begin
delivering primary endpoint results at the end of this year and into the first
half of next year, we are at the point where we are ready to begin building
XOMA's launch strategy and commercialization plans.The importance of creating
the sales and marketing plan for our first XOMA-developed product cannot be
underestimated. We will build on Tom's vast experience to develop a launch
program that maximizes the commercial potential of gevokizumab in the U.S. and
that we can successfully execute from the day we hopefully receive BLA
approval," stated Mr. Varian."The second reason for creating a CCO position
was to fully integrate market analyses into our clinical development
decisions. The ability to foresee the commercial landscape of a clinical
candidate early in the process is crucial to maximizing its commercial
potential.Tom will draw on his years of experience and his vast network to
provide our team with the most accurate information that will guide our
second, third and fourth gevokizumab indications.The team and I are looking
forward to working closely with Tom to ensure gevokizumab is a commercial
success in the United States."

During his tenure with Genentech, Mr. Klein worked closely with both the Roche
and Genentech teams to develop and execute commercial integration plans that
met the needs of each company in their respective territories.Mr. Klein
joined Genentech from Roche, where he had direct oversight over the Roche
Hepatology and HIV Sales and Marketing teams and was responsible for ensuring
affiliate and global strategic alignment.Prior to his 12 years with Roche,
Mr. Klein spent 11 years with Westwood-Squibb/Bristol Myers-Squibb in a
several sales and product management roles.Mr. Klein has launch experience in
both the specialty and primary care markets, most recently with Boniva®
(ibandronate sodium) for the treatment of osteoporosis in postmenopausal
women. He also has been responsible for the category leading growth of
Pegasys® (peginterferon alpha-2a) in HCV and market leadership of Pulmozyme®
(dornase alfa) in cystic fibrosis, a rare disease area.Mr. Klein has a BA,
Marketing, from Pennsylvania State University and an MBA, Management from
Temple University.

"After spending my career at some of the leading pharmaceutical and
biotechnology companies, the opportunity to build a commercial organization
from the ground up with gevokizumab as the cornerstone is incredibly
appealing," commented Mr. Klein."I am excited to be a part of the leadership
team XOMA has attracted to drive this next chapter in the Company's history
and to be part of an effort to improve so many patients' lives." 

AboutXOMA

XOMAcombines a portfolio of innovative therapeutic antibodies, both in
late-stage clinical development and in preclinical research, with its recently
launched commercial operations.XOMAfocuses its antibody research and
development on allosteric modulation, which offers opportunities for new
classes of therapeutic antibodies to treat a wide range of human
diseases.XOMA is developing its lead product gevokizumab (IL-1 beta
modulating antibody) withServierthrough a global Phase 3 program in
non-infectious uveitis and ongoing proof-of-concept studies in other
IL-1-mediated diseases.XOMA's scientific research also produced the XMet
program, which consists of three classes of preclinical antibodies, including
Selective Insulin Receptor Modulators (SIRMs) that could have a major effect
on the treatment of diabetes.

More detailed information can be found atwww.xoma.com.

The XOMACorporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5960

AboutServier

Servieris a privately run French research-based pharmaceutical company.
Current therapeutic domains forServiermedicines are cardiovascular,
metabolic, neurological, psychiatric and bone and joint diseases, as well as
oncology.Servieris established in 140 countries worldwide with over 20,000
employees and a 2011 turnover of €3.9 billion.Servierinvests 25% of its
turnover in R&D.

More information is available at:www.servier.com

Forward-Looking Statements

Certain statements contained in this press release including, but not limited
to, statements related to anticipated timing of completion of clinical trials,
the successful outcome of clinical trials, regulatory approval of unapproved
product candidates, anticipated commercial success of currently unapproved
products, or that otherwise relate to future periods are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.These statements are based
on assumptions that may not prove accurate, and actual results could differ
materially from those anticipated due to certain risks inherent in the
biotechnology industry and for companies engaged in the development of new
products in a regulated market.Potential risks to XOMA meeting these
expectations are described in more detail in XOMA's most recent filing on Form
10-K and in other SEC filings.Consider such risks carefully when considering
XOMA's prospects.Any forward-looking statement in this press release
represents XOMA's views only as of the date of this press release and should
not be relied upon as representing its views as of any subsequent date. XOMA
disclaims any obligation to update any forward-looking statement, except as
required by applicable law.

CONTACT: XOMA Corporation
        
         Company and Investor Contact:
         Ashleigh Barreto
         510-204-7482
         barreto@xoma.com
        
         Juliane Snowden
         The Oratorium Group, LLC
         jsnowden@oratoriumgroup.com
        
         Media Contact:
         Canale Communications
         Carolyn Hawley
         619-849-5375
         carolyn@canalecomm.com

XOMA Corporation Logo